Guyer William

Guyer William, Chief Development Officer of Corcept Therapeutics (CORT), has maintained a consistent and heavily sell-skewed position in the company's stock over the past year. Across 47 total Form 4 transactions, William has executed zero open-market purchases while recording approximately $16.9 million in sales. The pattern is unambiguous: every recent trade involving actual market conviction has been a disposition, with the most active selling occurring in the first half of 2026. The recent transaction history shows a mechanical rhythm of option exercises paired with same-day sales. On July 7, 2026, William exercised options valued at $433,000 and immediately sold shares worth roughly $1.86 million in two separate transactions. Similar paired exercises and sales occurred on June 2, May 5, April 7, and February 3, 2026, each time with the exercise value at $433,000 and sale proceeds ranging from $703,656 to $1.41 million. The largest single-day sale came on July 7, 2026, at $1.77 million, followed by $1.55 million on December 2, 2025. Smaller open-market sales of $423,729 and $296,346 in March 2026 round out the disposition pattern. The only non-sale activity consists of compensation-related grants and option exercises. William received equity awards on June 1, 2026 ($61,775) and March 2, 2026 ($17,913), along with a zero-value grant on February 27, 2026. These acquisitions are automatic compensation events, not discretionary purchases. The absence of any "P" coded buys, combined with the steady cadence of monthly option exercises and immediate sales, indicates that William has been systematically monetizing his equity compensation rather than accumulating additional CORT shares. The selling has been consistent across all reporting periods, with no recent shift toward accumulation.